EMA to revoke PIP oncology waivers, says more cancer trials needed in children
This article was originally published in Scrip
As a result of concerns that pharmaceutical companies are not conducting enough clinical trials in children, the European Medicines Agency's pediatrics committee (PDCO) is planning to revoke class waivers for paediatric investigation plans in some conditions on the grounds that the waivers are preventing the agency from requesting studies in children, especially in the field of oncology. The move would not affect drugs already on the market, unless they were submitted for review in additional indications.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.